203 related articles for article (PubMed ID: 32270320)
1. The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.
Olszewska B; Gleń J; Zabłotna M; Nowicki RJ; Sokołowska-Wojdyło M
Arch Dermatol Res; 2021 Jan; 313(1):25-31. PubMed ID: 32270320
[TBL] [Abstract][Full Text] [Related]
2. STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland.
Sławińska M; Zabłotna M; Gleń J; Lakomy J; Nowicki RJ; Sobjanek M
Arch Dermatol Res; 2019 Nov; 311(9):697-704. PubMed ID: 31342143
[TBL] [Abstract][Full Text] [Related]
3. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
4. Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease.
Malek M; Gleń J; Rębała K; Kowalczyk A; Sobjanek M; Nowicki R; Ruckemann-Dziurdzińska K; Sokołowska-Wojdyło M
Acta Derm Venereol; 2015 Mar; 95(3):283-8. PubMed ID: 25176053
[TBL] [Abstract][Full Text] [Related]
5. Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Ohmatsu H; Fujita H; Kagami S; Asano Y; Tada Y; Kadono T; Sato S
Acta Derm Venereol; 2013 Mar; 93(2):144-9. PubMed ID: 22948508
[TBL] [Abstract][Full Text] [Related]
6. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
Cedeno-Laurent F; Singer EM; Wysocka M; Benoit BM; Vittorio CC; Kim EJ; Yosipovitch G; Rook AH
Clin Immunol; 2015 May; 158(1):1-7. PubMed ID: 25762519
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3.
Nielsen M; Nissen MH; Gerwien J; Zocca MB; Rasmussen HM; Nakajima K; Röpke C; Geisler C; Kaltoft K; Ødum N
Blood; 2002 Feb; 99(3):973-7. PubMed ID: 11807001
[TBL] [Abstract][Full Text] [Related]
9. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
[TBL] [Abstract][Full Text] [Related]
10. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
[TBL] [Abstract][Full Text] [Related]
11. The role of polymorphism of
Nedoszytko B; Olszewska B; Roszkiewicz J; Glen J; Zabłotna M; Ługowska-Umer H; Nowicki R; Sokołowska-Wojdyło M
Postepy Dermatol Alergol; 2016 Dec; 33(6):429-434. PubMed ID: 28035219
[TBL] [Abstract][Full Text] [Related]
12. Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Senda N; Miyagaki T; Kamijo H; Nakajima R; Oka T; Takahashi N; Suga H; Yoshizaki A; Asano Y; Sugaya M; Sato S
Eur J Dermatol; 2018 Oct; 28(5):621-627. PubMed ID: 30378541
[TBL] [Abstract][Full Text] [Related]
13. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression.
Asadullah K; Haeussler-Quade A; Gellrich S; Hanneken S; Hansen-Hagge TE; Döcke WD; Volk HD; Sterry W
Exp Dermatol; 2000 Aug; 9(4):248-51. PubMed ID: 10949545
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-31 is overexpressed in skin and serum in cutaneous T-cell lymphomas but does not correlate to pruritus.
Olszewska B; Żawrocki A; Gleń J; Lakomy J; Karczewska J; Zabłotna M; Malek M; Jankau J; Lange M; Biernat W; Nowicki RJ; Sokołowska-Wojdyło M
Postepy Dermatol Alergol; 2022 Feb; 39(1):81-87. PubMed ID: 35369626
[TBL] [Abstract][Full Text] [Related]
15. Heterozygote AG variant of -596 A/G IL-6 gene polymorphism is a marker for cutaneous T-cell lymphoma (CTCL).
Vasku JA; Vasku A; Goldbergova M; Vasku V
Clin Immunol; 2004 Dec; 113(3):256-60. PubMed ID: 15507390
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
17. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
18. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway.
Krejsgaard T; Ralfkiaer U; Clasen-Linde E; Eriksen KW; Kopp KL; Bonefeld CM; Geisler C; Dabelsteen S; Wasik MA; Ralfkiaer E; Woetmann A; Odum N
J Invest Dermatol; 2011 Jun; 131(6):1331-8. PubMed ID: 21346774
[TBL] [Abstract][Full Text] [Related]
19. Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma.
Hirshberg B; Kramer MR; Lotem M; Barak V; Shustin L; Amir G; Ben-Yehuda D; Ben-Yehuda A
Am J Hematol; 1999 Feb; 60(2):143-7. PubMed ID: 9929108
[TBL] [Abstract][Full Text] [Related]
20. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.
Hu M; Scheffel J; Elieh-Ali-Komi D; Maurer M; Hawro T; Metz M
Clin Exp Med; 2023 Dec; 23(8):4177-4197. PubMed ID: 37555911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
